Products
Online Inquiry
WYE-687
Cat. No.:
0225LY-0557
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
WYE-687 acts as a selective and ATP-competitive mTOR inhibitor (IC50: 7 nM) that blocks mTORC1/pS6K and mTORC2/P-AKT without affecting P-AKT (T308); it shows high selectivity for mTOR over PI3K alpha (>100-fold) and PI3K gamma (>500-fold).
Synonym:
1062161-90-3; Methyl (4-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)carbamate; Methyl N-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate; Pyrazolo pyrimidine, 9; Methyl N-{4-[4-(morpholin-4-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl}carbamate; Methyl {4-[4-(morpholin-4-yl)-1-{1-[(pyridin-3-yl)methyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl}carbamate
CAS No.:
1062161-90-3
Compound CID:
25229450
Formula:
C28H32N8O3
Formula Weight:
528.61
Specification
Targets&IC50:
mTOR: 7 nM
Relative Density:
1.40 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
WYE-687 can be used in metabolic and oncogenic research to examine the simultaneous inhibition of mTORC1 and mTORC2 complexes.
Library Information
Target:
PI3K; p38 MAPK; Src; mTOR
Receptor:
mTOR; p38α; PI3Kα; PI3Kγ; Src
Pathways:
MAPK; Angiogenesis; PI3K/Akt/mTOR signaling; Tyrosine kinase/adaptors
Plate Number:
AOCL-8
Plate Location:
b11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60.2 mg/mL; 113.88 mM
Water Max Solubility:
60.2 mg/mL; 113.88 mM
